RNA-Powered cell therapy takes on autoimmune diseases
NCT ID NCT07322718
First seen Jan 08, 2026 · Last updated May 01, 2026 · Updated 15 times
Summary
This early-phase study tests a new treatment called RXIM002 for people with severe autoimmune diseases that haven't responded to standard therapies. RXIM002 uses circular RNA to create CAR T-cells inside the body that target and destroy faulty B-cells. The main goals are to check safety and how the body handles the therapy, with 27 adults expected to participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B CELL-MEDIATED AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, Huangpu District, No. 197, Ruijin 2nd Road, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.